Skip to main content

Table 5 ANOVA and t-test results of clinical characteristics

From: EQ-5D-5L and SF-6Dv2 health utilities scores of diffuse large B-cell lymphoma patients in China

 

n

(%)

EQ-5D-5L

SF-6Dv2

Mean

SD

F /t

P-value

Mean

SD

F /t

P-value

Overall

582

 

0.828

0.222

  

0.641

0.220

 

 < 0.001

Treatment status

 Initial treatment

477

(81.96)

0.841

0.211

3.02

0.003

0.653

0.214

2.81

0.005

 RR treatment

105

(18.04)

0.769

0.260

  

0.586

0.236

  

Whether on treatment

 Untreated

2

(0.34)

0.857

0.203

30.66

 < 0.001

0.636

0.290

58.69

0.037

 On treatment

162

(27.84)

0.718

0.286

  

0.496

0.226

  

 Off treatment

418

(71.82)

0.871

0.175

  

0.697

0.190

  

Treatment evaluation

 CR

389

(66.84)

0.869

0.176

15.69

 < 0.001

0.690

0.191

25.42

 < 0.001

 PR

75

(12.89)

0.789

0.229

  

0.594

0.217

  

 PD

29

(4.98)

0.686

0.319

  

0.474

0.290

  

 Have not been evaluated

89

(15.29)

0.731

0.298

  

0.518

0.233

  

IPI score

 IPI = 0 ~ 1 (low risk)

162

(36.16)

0.884

0.126

13.99

 < 0.001

0.691

0.168

12.62

 < 0.001

 IPI = 2 (medium risk)

114

(25.45)

0.851

0.178

  

0.671

0.211

  

 IPI = 3 ~ 5 (high risk)

172

(38.39)

0.770

0.268

  

0.582

0.243

  

a134 respondents were Unknown

Double-hit/Triple-hit (DHL/THL)

 Yes

49

(11.26)

0.775

0.247

2.41

0.017

0.620

0.210

1.25

0.213

 No

386

(88.74)

0.849

0.195

  

0.660

0.200

  

a147 respondents were Unknown

Double-expressor (DEL)

 Yes

166

(38.88)

0.799

0.254

3.52

 < 0.001

0.598

0.237

3.96

 < 0.001

 No

261

(61.12)

0.868

0.153

  

0.679

0.179

  

a155 respondents were Unknown

Non-GCB subtype/ABC subtype

 Yes

300

(72.64)

0.820

0.227

0.95

0.344

0.628

0.220

1.26

0.207

 No

113

(27.36)

0.843

0.207

  

0.658

0.201

  

a169 respondents were Unknown

TP53 mutation

 Yes

76

(23.17)

0.783

0.290

2.59

0.010

0.598

0.255

2.61

0.009

 No

252

(76.83)

0.857

0.192

  

0.669

0.194

  

a254 respondents were Unknown

MYD88 mutation and/or CD79b mutation

 CD79b mutation

13

(5.39)

0.794

0.226

4.96

0.002

0.623

0.223

5.1

0.002

 MYD88 mutation

31

(12.86)

0.705

0.310

  

0.517

0.259

  

 Both

34

(14.11)

0.794

0.276

  

0.615

0.226

  

 Neither

163

(67.63)

0.866

0.192

  

0.674

0.197

  

a341 respondents were Unknown

Ann Arbor staging

 Stage I

74

(14.92)

0.906

0.110

9.73

 < 0.001

0.729

0.141

9.3

 < 0.001

 Stage II

118

(23.79)

0.867

0.132

  

0.666

0.170

  

 Stage III

87

(17.54)

0.862

0.177

  

0.665

0.200

  

 Stage IV

217

(43.75)

0.776

0.276

  

0.589

0.258

  

a86 respondents were Unknown

Complication

 Have at least one complication

240

(41.24)

0.851

0.205

3.02

0.003

0.597

0.232

4.08

 < 0.001

 Have no complication

342

(58.76)

0.795

0.241

  

0.671

0.206

  
  1. The test statistic provided a t-value for the comparison of two groups and the F-statistic is provided from ANOVA when comparing more than two groups
  2. The p-value in the upper right corner represents the significant level of the means of the two scales in the overall patients, and is written in italics
  3. Bold value = statistically significant difference at 0.05
  4. CR complete remission, PR partial remission, PD progressive disease, Unknown respondents whose progression has not been evaluated
  5. aUnknown respondents of IPI score, DHL/THL, DEL, Non-GCB subtype/ABC subtype, TP53 mutation, MYD88 mutation and/or CD79b mutation, Ann Arbor staging was not included in ANOVA or t-test analysis
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us